Abstract
e15509 Background: There is some evidence that BEV, an anti-VEGF monoclonal antibody, is active on OC. The goal of this study was to assess the combination of BEV and chemotherapy in heavily pretreated OC patients (pts) with regard to efficacy and toxicity. Methods: In this retrospective multicentric analysis, heavily pretreated OC pts receiving BEV with chemotherapy were assessed for efficacy with CA125 measurement and CT-scans. Toxicity was assessed according to NCI-CTC V3.0. Results: 43 pts from six oncologic centers were identified and included. The median number of prior chemotherapy regimen was 3 (range 1-13). BEV was combined with paclitaxel in 30 pts (69.7%), docetaxel in 9 (20.9%), and other agents in 4 (9.3%). The median number of treatment cycles was 6 (range 1-29). No toxic death was reported. Grade 3-4 toxic events occurred in 13 (30.2%) pts, including proteinuria, elevated blood pressure, hemorrhage, pelvic abscess and psychiatric disorders. Gastrointestinal perforations (GIP) and fistulas occurred in 3 (7.0%) and 6 (13.9%) pts, respectively. GIP occurred in 7% versus 0% of pts who received 4-7 and 2 prior regimens, respectively. Only 1 (2.3%) patient had venous thrombo-embolic event, whereas no arterial embolic complication was reported. The clinical benefit defined as complete (CR) and partial (PR) responses plus stable disease ≥ 3 months was 65%. The objective response rate was 40%, including 6 (15%) CR and 10 (25%) PR. Median time to progression was 3.8 months (range 0.2 -14.4 months). At last follow-up (Dec. 09), 13 pts (30.2%) were still on BEV treatment, and 31 (72%) were alive. Conclusions: The combination of chemotherapy and BEV in routine practice is feasible and active in heavily pretreated OC pts. Toxicity is manageable, but GIP and fistulas are of concern. Further studies are warranted to assess BEV plus taxanes in advanced OC. No significant financial relationships to disclose.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
